Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Soligenix Inc (SNGX)

Soligenix Inc (SNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,936
  • Shares Outstanding, K 10,086
  • Annual Sales, $ 120 K
  • Annual Income, $ -8,270 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 1.83
  • Price/Sales 136.46
  • Price/Cash Flow N/A
  • Price/Book 2.09

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2500 +30.39%
on 11/13/25
1.6700 -2.40%
on 12/05/25
+0.2599 (+18.97%)
since 11/07/25
3-Month
1.1100 +46.84%
on 09/30/25
2.9800 -45.31%
on 09/12/25
-1.0501 (-39.18%)
since 09/09/25
52-Week
1.0900 +49.53%
on 07/08/25
6.2299 -73.84%
on 08/18/25
-1.8601 (-53.30%)
since 12/09/24

Most Recent Stories

More News
Soligenix (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone

When a late-stage clinical trial reports response rates nearly double what researchers expected, yet the stock market barely reacts, seasoned analysts take notice and wonder if investors are missing something...

SNGX : 1.6200 (+2.53%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Featured in BioMedWire Editorial on Rare Disease Therapies

Soligenix (NASDAQ: SNGX), announces its inclusion in a BioMedWire editorial examining the urgent rise of chronic and rare diseases in aging populations. With more than 30 million Americans living with...

SNGX : 1.6200 (+2.53%)
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad

NEW YORK, Dec. 05, 2025 (GLOBE NEWSWIRE) -- via BioMedWire : — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the ...

SNGX : 1.6200 (+2.53%)
Soligenix (NASDAQ: SNGX) Featured in BioMedWire Editorial Highlighting HyBryte(TM) and Rare Disease Policy

Soligenix (NASDAQ: SNGX) was featured in a BioMedWire editorial titled “Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now,” which examines the growing burden of rare...

SNGX : 1.6200 (+2.53%)
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space

NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- via BioMedWire : — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the ...

SNGX : 1.6200 (+2.53%)
Soligenix (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate

In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly...

SNGX : 1.6200 (+2.53%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating...

SNGX : 1.6200 (+2.53%)
Soligenix (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advance

Soligenix (NASDAQ: SNGX) is entering a new phase of strategic breadth and influence with the appointment of a seasoned, high-level scientific and policy adviser who brings rarefied experience at the intersection...

SNGX : 1.6200 (+2.53%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues

In a key development that underscores the advancing clinical trajectory of its lead therapy, Soligenix (NASDAQ: SNGX) announced that the Data Monitoring Committee (“DMC”) overseeing its confirmatory...

SNGX : 1.6200 (+2.53%)
BMWYY : 29.2000 (+4.58%)
Soligenix (NASDAQ: SNGX) Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases with unmet medical need, completed enrollment of the 50 patients required for the interim analysis...

SNGX : 1.6200 (+2.53%)

Business Summary

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable...

See More

Key Turning Points

3rd Resistance Point 1.7459
2nd Resistance Point 1.6829
1st Resistance Point 1.6315
Last Price 1.6200
1st Support Level 1.5171
2nd Support Level 1.4541
3rd Support Level 1.4027

See More

52-Week High 6.2299
Fibonacci 61.8% 4.2665
Fibonacci 50% 3.6600
Fibonacci 38.2% 3.0534
Last Price 1.6200
52-Week Low 1.0900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar